Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm. Established in 2015 and headquartered in Oslo, Norway, Curida is an integrated Contract Development and Manufacturing Organization (“CDMO”) specializing in the use of blow-fill-seal (“BFS”) and nasal spray technologies, as well as antibody manufacturing. Curida provides outsourced development and manufacturing of aseptic and non-aseptic liquid BFS and nasal spray formatted drugs, and serves the diagnostics industry with monoclonal antibodies. Curida’s customer base ranges from small to medium-sized pharmaceutical, medical devices, and biotech companies, delivering solutions in drug development and GMP manufacturing globally.
Read the full article: Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners //
Source: https://www.businesswire.com/news/home/20240416093461/en/Curida-Small-Molecules-and-Biologics-CDMO-Secures-Private-Equity-Investment-from-Signet-Healthcare-Partners